Dec 12 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Inside a lab at the Massachusetts Institute of Technology late last year, scientists gave an AI system a new task: designing entirely new molecules for potential antibiotics from scratch. Within a day ...

When "Dilbert" creator Scott Adams recently made a public plea for help accessing a life-extending cancer treatment, the story drew national attention — and sparked some questions about the drug ...

A promising “two-in-one” experimental drug could tackle both type 2 diabetes and heart disease by slashing cholesterol and inflammation, potentially offering a powerful new way to protect the heart ...

B King became the focus of a murder probe after he and DJ Regio Clown were slain in a turf war over Mexico’s lucrative pink “tusi” drug. B King became the center of a deadly criminal probe after his ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer. Adding the drug enzalutamide to standard hormone therapy reduced the risk of ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, lowering the risk of death after eight years by 40.3%. What's more, the drug ...

Human epidermal growth factor receptor 2 (HER2)–directed antibody–drug conjugate monotherapy has shown preliminary clinical efficacy in patients with chemotherapy-refractory HER2-positive locally ...

Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not candidates for inhibitors of programmed cell death protein 1 (PD-1) or ...

Dianthus Therapeutics and Boehringer Ingelheim headlined the latest round of licensing deals featuring Chinese biotechs. Fierce's deep dive into the dispute between Novo Nordisk and KBP Biosciences ...

Oct 14 (Reuters) - U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda Pharmaceutical (4502.T), opens new tab, deepening their ...